HYDROXYCARBAMIDE

Clinical Indication

Myeloproliferative disorders, sickle cell anaemia

Comments

Full SCA

Date of classification

January 2010

Orange

Shared Care Agreement. Higher risk medicines requiring significant regular monitoring which would be initiated by or at the recommendation of a specialist service which may include mental health services, secondary care, tertiary care, community providers, private providers and GPs with a specialist interest.